CEO research orientation, organizational context, and innovation in the pharmaceutical industry

被引：21
|
作者：
van de Wal, Nino [1 ]
Boone, Christophe [1 ]
Gilsing, Victor [1 ,2 ]
Walrave, Bob [3 ]
机构：
[1] Univ Antwerp, Dept Management, ACED, Antwerp, Belgium
[2] Vrije Univ Amsterdam, Sch Business & Econ, Amsterdam, Netherlands
[3] Eindhoven Univ Technol, Sch Ind Engn, Eindhoven, Netherlands
来源：
R & D MANAGEMENT | 2020年 / 50卷 / 02期
关键词：
TOP MANAGEMENT TEAM; UPPER ECHELONS; FIRM; PERFORMANCE; LEADERSHIP; CULTURE; DETERMINANTS; EXPLORATION; PERSPECTIVE; EVOLUTION;
D O I：
10.1111/radm.12394
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
This study develops and tests a comprehensive framework that explains what, when, and how CEO characteristics influence firms' innovation outcomes in R&D-intensive industries. Empirical evidence from 109 CEOs from 87 U.S.-based pharmaceutical firms over the period 2001-2013 reveals that research-oriented CEOs - those with ability and motivation for science and technology - increase their firms' innovation outcomes. The results indicate that the CEO-innovation relationship strongly depends on the extent of CEOs' managerial discretion, which is shaped by the organizational context. We contribute to a more comprehensive understanding of the role of CEOs in firms ' innovation performance differentials.
引用
收藏
页码：239 / 254
页数：16
相关论文
共 50 条
  • [31] The Role of Desorptive Capacity in the Relationship of Entrepreneurial Orientation - Open Innovation Performance: The Case of the Pharmaceutical Industry
    Yektadoost, Alireza
    Saeedi, Mohammad Reza
    Kebriaeezadeh, Abbas
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2021, 20 (01): : 118 - 132
  • [32] Social and organizational capital: The context for innovation
    Cabello-Medina, Carmen
    Carmona-Lavado, Antonio
    Cuevas-Rodrigues, Gloria
    ISMOT'07: PROCEEDINGS OF THE FIFTH INTERNATIONAL SYMPOSIUM ON MANAGEMENT OF TECHNOLOGY, VOLS 1 AND 2: MANAGING TOTAL INNOVATION AND OPEN INNOVATION IN THE 21ST CENTURY, 2007, : 794 - 798
  • [33] Innovation and merger decisions in the pharmaceutical industry
    Morgan, EJ
    REVIEW OF INDUSTRIAL ORGANIZATION, 2001, 19 (02) : 181 - 197
  • [34] The role of users in innovation in the pharmaceutical industry
    Smits, Ruud E. H. M.
    Boon, Wouter P. C.
    DRUG DISCOVERY TODAY, 2008, 13 (7-8) : 353 - 359
  • [35] INNOVATION IN PHARMACEUTICAL INDUSTRY - SCHWARTZMAN,D
    HERENDEEN, JB
    SOUTHERN ECONOMIC JOURNAL, 1978, 44 (04) : 1031 - 1032
  • [36] Is declining innovation in the pharmaceutical industry a myth?
    Schmid, EF
    Smith, DA
    DRUG DISCOVERY TODAY, 2005, 10 (15) : 1031 - 1039
  • [37] Models for open innovation in the pharmaceutical industry
    Schuhmacher, Alexander
    Germann, Paul-Georg
    Trill, Henning
    Gassmann, Oliver
    DRUG DISCOVERY TODAY, 2013, 18 (23-24) : 1133 - 1137
  • [38] Manufacturing Process Innovation in the Pharmaceutical Industry
    Lugovoi, Ivan
    Andritsos, Dimitrios A.
    Senot, Claire
    M&SOM-MANUFACTURING & SERVICE OPERATIONS MANAGEMENT, 2022, 24 (03) : 1760 - 1778
  • [39] COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY
    DIMASI, JA
    HANSEN, RW
    GRABOWSKI, HG
    LASAGNA, L
    JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) : 107 - 142
  • [40] Innovation crisis in the pharmaceutical industry? A survey
    Ute Laermann-Nguyen
    Martin Backfisch
    SN Business & Economics, 1 (12):
12345